SCHEMBL29618010

SCHEMBL29618010

CCOC(=O)c1ncn2c1CNC(=O)c1cc(Cl)ccc1-2

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 10/20 0.69
GABRB3 P28472 10/20 0.69
GABRA5 P31644 10/20 0.69
GABRA1 P14867 7/20 0.69
GABRA3 P34903 7/20 0.69
GABRA2 P47869 7/20 0.69
GABRA6 Q16445 6/20 0.69
GABRB2 P47870 3/20 0.69
GABRA4 P48169 2/20 0.69
MEN1 O00255 1/20 0.53
GABRP O00591 1/20 0.53
GABRD O14764 1/20 0.53
ALDH1A1 P00352 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
TSHR P16473 1/20 0.53
GABRB1 P18505 1/20 0.53
CYP2C19 P33261 1/20 0.53
GABRE P78334 1/20 0.53
KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18329262 1.00 GABRG2 (0.69) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL6870825 0.90 GABRG2 (0.63) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL9262692 0.89 GABRG2 (0.65) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL6867089 0.89 GABRG2 (0.70) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL30661077 0.88 GABRG2 (0.69) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL7330808 0.88 GABRG2 (0.69) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL6873122 0.87 GABRG2 (0.65) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL6866680 0.86 GABRG2 (0.54) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL9260791 0.85 GABRG2 (0.67) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL7037721 0.84 GABRG2 (0.60) GABRG2GABRB3GABRA5GABRA1GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528819-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2026-01-20 US disclosed
US-12291535-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2025-05-06 US disclosed
US-12024525-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2024-07-02 US disclosed
US-20230134844-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO, INC. 2023-05-04 US disclosed
US-20230107032-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-04-06 US disclosed
US-11505555-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2022-11-22 US disclosed
US-20220274996-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO, INC. 2022-09-01 US disclosed
US-11414425-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2022-08-16 US disclosed
US-11312721-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2022-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12024525-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GRM5, GABRA5, GABRE GABRG2 24/4885GABRB3 15/4885GABRA5 2/4885
US-11505555-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GRM5, GABRA5, GABRE GABRG2 20/4885GABRB3 15/4885GABRA5 2/4885
US-12528819-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GABRA5, GRM5, GABRE GABRG2 20/4885GABRB3 11/4885GABRA5 1/4885
US-11312721-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GRM5, GABRA5, GABRE GABRG2 22/4885GABRB3 16/4885GABRA5 2/4885
US-20230107032-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT GABRA5, GRM5, GABRA1 GABRG2 14/4885GABRB3 11/4885GABRA5 1/4885
US-11414425-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GABRA5, GRM5, GABRA1 GABRG2 14/4885GABRB3 11/4885GABRA5 1/4885
US-20220274996-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT GRM5, GABRA5, GABRE GABRG2 24/4885GABRB3 15/4885GABRA5 2/4885
US-12291535-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GABRA5, GRM5, GABRA1 GABRG2 14/4885GABRB3 11/4885GABRA5 1/4885
US-20230134844-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT GRM5, GABRA5, GABRE GABRG2 20/4885GABRB3 15/4885GABRA5 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.